Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > OctoPlus announces update on publication of positive Locteron interim Phase IIb data

OctoPlus announces update on publication of positive Locteron interim Phase IIb data

Leiden, the Netherlands | Posted on March 17th, 2010

OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces that two further abstracts containing preliminary Locteron® Phase IIb clinical results have just been published. These abstracts were submitted by OctoPlus' licensee Biolex and have been accepted for poster presentations on 15 April 2010 during the 45th International Liver Congress in Vienna, Austria. The poster presentations at the conference will contain final results from two Phase IIb studies after 12 weeks of treatment with Locteron compared to PEG-Intron®.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus
OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus’ proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics’ lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

About Locteron
Locteron is a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron combines OctoPlus’ controlled release drug delivery technology PolyActive® with Biolex’ interferon alpha and is the most advanced product in clinical development incorporating one of OctoPlus’ proprietary drug delivery technologies. OctoPlus licensed its commercial rights to Locteron exclusively to Biolex in October 2008.

For more information, please click here

Contacts:
Rianne Roukema
Corporate Communications
telephone +31 (71) 524 1071
Investor Relations at

Copyright © OctoPlus

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Cool Calculations for Cold Atoms: New theory of universal three-body encounters September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Nanomedicine

UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Nano-forests to reveal secrets of cells September 2nd, 2014

Nanoscale assembly line August 29th, 2014

Announcements

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE